We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has granted priority review designation to Pfizer’s and BioNTech’s Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in people 16 years of older. Read More
Pfizer has agreed to a $345 million settlement of a class action antitrust suit over the EpiPen, an epinephrine auto-injector used in the emergency treatment of anaphylaxis. Read More
How do you determine a drug’s cost/benefit ratio when you know the cost to procure and administer it could soar to $100,000 each year, but the benefit could be zero? Read More
GlaxoSmithKline released positive topline results from five clinical studies of daprodustat, its investigational drug for treatment of anemia that occurs with chronic kidney disease (CKD). Read More
San Francisco biotech FibroGen’s investigational drug for anemia linked to chronic kidney disease (CKD) should not receive FDA approval, the agency’s Cardiovascular and Renal Drugs Advisory Committee said yesterday. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization’s COVAX program are launching a “marketplace” to make use of unused materials and idle stock to increase the global production of COVID-19 vaccines for underserved populations. Read More
Mount Sinai Hospital in New York and Cleveland Clinic are the latest large players in healthcare to flash a red light at Biogen’s controversial new Alzheimer’s drug Aduhelm. Read More
The Jan. 4 proposal by NIST would have weakened one of the few tools the federal government has to directly reduce the price of new prescription drugs. Read More